Stay updated with breaking news from Emyria Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In 2023, the healthcare sector faced challenges in keeping pace with the broader equity market. However, Janus Henderson portfolio managers Andy Acker and...
Emyria Ltd has safely dosed its first participant of its ethics-approved MDMA-assisted therapy (MDMA-AT) trial, EMDMA-001. This is a significant milestone...
Clinical services and drug development company Emyria Ltd (ASX:EMD) has received a high level of support from shareholders, raising $1.18 million in an ...
Rebounding from an 11 month low reached yesterday, the ASX 200 ended the day higher, gaining 0.62%. Real estate led the gains and the major banks rallied,...
Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has secured an immediately available local supply of MDMA, the final component that allows...